Peptide Receptor Radionuclide Therapy (PRRT) for the Treatment of Neuroendocrine Tumors

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

50 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-28

Study Completion Date

2024-06-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The specific aim is of this study is to gain a better understanding of the patient characteristics, treatment responses, survival outcomes, and adverse events associated with PRRT in patients with gastroenteropancreatic primary NETs.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of PRRT in Metastatic, World Health Organization (WHO) Grade 1 or 2, SSTR Positive, GEP-NET Who Are Candidates for Cytoreductive Surgery

NCT04609592

Gastroenteropancreatic Neuroendocrine Tumor

RECRUITING PHASE1

Personalized PRRT of Neuroendocrine Tumors

NCT02754297

Neuroendocrine Tumors Carcinoid Tumor Carcinoma, Neuroendocrine

ACTIVE_NOT_RECRUITING PHASE2

Efficacy and Safety of 177Lu-Dotatate PRRT in Metastatic GEP-NEN Patients

NCT03422029

Neuroendocrine Tumors

UNKNOWN PHASE2

Peptide Receptor Radionuclide Therapy (PRRT) in Tumors With High Expression of Somatostatin Receptors (Phase 2)

NCT04790708

Neuroendocrine Tumors Peptide Receptor Radionuclide Therapy (PRRT)

UNKNOWN NA

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

NCT03273712

Neuroendocrine Tumors Meningioma Neuroblastoma +1 more

COMPLETED PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Neuroendocrine tumors (NETs) make up a large range of malignancies that arise from neuroendocrine cells in multiple organs of the body. Hallet et al conducted a large population-based study that demonstrated that 21% of NET patients presented with metastatic disease and another 38% developed metastases after resection of the primary tumor (Hallet et al., 2015). This burden demonstrates the need for effective systemic therapy for advanced NETs. Options for systemic therapy include peptide receptor radionuclide therapy (PRRT).

A need for more prospective series are needed on treatment responses and survival outcomes related to gastroenteropancreatic primary NETs treated with PRRT was identified. Thus the purpose of this study is to collect clinical data related to treatment of gastroenteropancreatic primary NETs s with PRRT. Clinical data related to patient characteristics, treatment responses and survival outcomes related to the treatment of gastroenteropancreatic primary NETs with PRRT and on adverse events and complications related to PRRT treatment will be collected.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Neuroendocrine Tumors

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treated w PRRT

Patients who received treatment of gastroenteropancreatic primary NETs with PRRT per the treating physicians discretion.

Peptide Receptor Radionuclide Therapy

Intervention Type PROCEDURE

a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Peptide Receptor Radionuclide Therapy

a molecular therapy (also called radioisotope therapy) used to treat a specific type of cancer called neuroendocrine tumors or NETs

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. \> 18 years of age
2. Diagnosed with gastroenteropancreatic primary NET and has consented to undergo PRRT per the treating physician. Specifically:

* Will consider other primaries on a case by case basis if dotatate scan (+) and meet all other criteria.
* Metastatic or Locally Advanced AND Inoperable
* Clear disease progression on Octreotide over less than 3 years (RECIST 1.1)
* Presence of disease within 24 weeks as identified by PET/CT scans with Ga-68 DOTATATE reporting the Krenning score for low-grade NET and/or PET/CT scans with FDG for transformation to high-grade NET
* Well differentiated on path - Ki67 \< 20%
* Octreotide positive on pathology (if not documented, acceptable if PET/CT imaging shows lesions with Ga-68 DOTATATE uptakeLabs:

* Cr. \<1.7
* Hgb \>8
* WBC \>2K
* Plt \>75K
* Bili \< 3x normal limit
* No Octreotide within 30 days of administration.
3. Willing and able to comply with the protocol requirements
4. Able to comprehend and sign the Informed Consent Form in English.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No